Drug information of Brolucizumab


Drug group:

Brolucizumab is made from a human antibody fragment. It works by keeping new blood vessels from forming under the retina (a sensory membrane that lines the inside of the eye). In people with certain types of eye disorders, new blood vessels grow under the retina where they leak blood and fluid

Brolucizumab ophthalmic (for the eyes) is used to treat the "wet form" of age-related macular degeneration

Mechanism of effect

Brolucizumab is a recombinant humanized monoclonal antibody vascular endothelial growth factor (VEGF) inhibitor that binds to the 3 major isoforms of VEGF-A, thereby suppressing endothelial cell proliferation, neovascularization, and vascular permeability to slow vision loss


Not fully characterized; free brolucizumab is expected to undergo proteolysis
Time to reach the peak
Serum: 24 hours (free brolucizumab
Half life: 4.4 ± 2 days

Drug indications

Neovascular (wet) age-related macular degeneration: Treatment of neovascular (wet) age-related macular degeneration


Usual Adult Dose for Macular Degeneration
Initial dose: 6 mg by intravitreal injection once a month for the first 3 doses
Maintenance dose: 6 mg by intravitreal injection once every 8 to 12 weeks

Drug contraindications

Patients with ocular or periocular infections

Patients with active intraocular inflammation

Hypersensitivity to the active drug or any product excipients

Safety and efficacy have not been established in patients younger than 18 years

Hypersensitivity (eg, rash, pruritus, urticaria, erythema, severe intraocular inflammation) to brolucizumab or any component of the formulation; ocular or periocular infections; active intraocular inflammation

Side effects

Immunologic: Antibody development 
 to 10%
Cardiovascular: Arterial thromboembolism
Hypersensitivity: Hypersensitivity reaction
Ophthalmic: Abnormal sensation in eyes, blindness, blurred vision, cataract, conjunctival hemorrhage, conjunctival hyperemia, conjunctivitis, corneal abrasion, endophthalmitis, eye pain, increased intraocular pressure, increased lacrimation, intraocular inflammation, punctate keratitis, retinal artery occlusion, retinal detachment, retinal hemorrhage, retinal hole without detachment, retinal pigment epithelium detachment, retinal pigment epithelium tear, vitreous detachment, vitreous opacity
Postmarketing: Ophthalmic: Retinal vein occlusion


There are no known significant interactions


This medicine may cause blurred vision and may impair your reactions. Avoid driving or hazardous activity until you know how this medicine will affect you

Intravitreal injections may be associated with endophthalmitis and retinal detachment. Use proper aseptic injection technique. Monitor for and report symptoms (eg, eye pain, redness of the eye, photophobia, blurred vision) immediately

Acute (within 30 minutes) and sustained increases in increased intraocular pressure (IOP) have occurred. Monitor IOP (via tonometry) and optic nerve head perfusion immediately following administration and manage appropriately

Cases of retinal vasculitis and/or retinal vascular occlusion have been reported; usually associated with intraocular inflammation. Monitor for and report any changes in vision immediately

Risk of arterial thromboembolic events (eg, nonfatal stroke, nonfatal myocardial infarction, vascular death) may be increased with intravitreal use of vascular endothelial growth factor inhibitors

Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect
Vision changes
Eye pain
Severe eye irritation
Eye redness
Sensitivity to light
Heart attack like chest pain; pain in arms, back, neck, jaw, or abdomen; shortness of breath; cold sweats; severe dizziness; passing out; or severe nausea or vomiting
Weakness on 1 side of the body, trouble speaking or thinking, change in balance, drooping on one side of the face, or blurred eyesight
Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat

Points of recommendation

You should not use brolucizumab if you are allergic to it, or if you have
inflammation inside your eye
an infection in or around your eye

Tell your doctor if you have ever had
a stroke

Do not use brolucizumab if you are pregnant. It could harm the unborn baby or cause birth defects. Use effective birth control to prevent pregnancy while you are receiving brolucizumab ophthalmic and for at least 1 month after your last dose

Do not breastfeed while receiving this medicine, and for at least 1 month after your last dose

Brolucizumab is given as an injection into your eye. Your doctor will use a medicine to numb your eye before giving you the injection. You will receive this injection in your doctor's office or other clinic setting

For a short time after your injection, your eyes will be checked periodically to make sure the injection has not caused any side effects

Brolucizumab is usually given once per month for 3 months, and then once every 8 to 12 weeks

Follow your doctor's dosing instructions very carefully. The timing of your monthly injections is very important for this medication to be effective

This drug should be administered by a qualified physician

Once monthly injections should be administered approximately every 25 to 31 days

In clinical trials, the maintenance dosing interval was guided by visual and anatomical measures of disease activity; the utility of these measures has not been established

Store refrigerated 2C to 8C; do not freeze
Prior to use, keep in outer carton to protect from light

Prior to use, the unopened vial may be kept at room temperature 20C to 25C for up to 24 hours

Injection should occur immediately after dose preparation; the product labeling may be consulted for injection procedure

A single vial should be used to treat a single eye; if the contralateral eye requires treatment, a new vial should be used and the sterile field, syringe, gloves, drapes, eyelid speculum, filter, and injection needles should be changed before administration to the other eye

Pregnancy level

Brolucizumab is a vascular endothelial growth factor (VEGF) inhibitor; VEGF is required to achieve and maintain normal pregnancies. Based on findings in animal reproduction studies and on the mechanism of action, brolucizumab may cause fetal harm if administered to a pregnant female

Drug forms


Ask a Pharmacist

User's questions
    No comments yet.